Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia
- PMID: 29201587
- PMCID: PMC5688038
- DOI: 10.1007/s13205-017-1019-8
Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia
Abstract
In this study, we examined mutations in the quinolone resistance-determining regions (QRDRs) of the gyrA and parC genes of Pseudomonas aeruginosa (P. aeruginosa) clinical isolates collected from patients hospitalized in University Hospital of Monastir, Tunisia. A total of 81 P. aeruginosa strains, obtained from clinical specimens, were included in the present study. Isolates were tested against 11 different antibiotics by a disk diffusion method. Minimum inhibitory concentrations (MICs) of ciprofloxacin were evaluated by E test method. The gyrA and parC sequences genes amplified by polymerase chain reaction (PCR) were sequenced. The highest resistance rates were found for ciprofloxacin (100%), gentamicin (96%) and ticarcillin (93%). The lower resistance rates were obtained for imipenem (74%) and ceftazidime (70%). Notably, 54% of isolates resistant to ciprofloxacin were determined to be multi-drug resistant. The investigation of mutations in the nucleotide sequences of the gyrA and parC genes showed that 77% of isolates have a single mutation in both gyrA (Thr-83 → Ile) and parC (Ser-87 → Leu). The emergence of ciprofloxacin resistance in clinical P. aeruginosa requires the establishment of appropriate antibiotherapy strategies in order to prescribe the most effective antibiotic treatment for preventing the emergence of multi-drug-resistant (MDR) P. aeruginosa strains.
Keywords: Ciprofloxacin; Mutations; Pseudomonas aeruginosa; Resistance; gyrA; parC.
Conflict of interest statement
The authors declare that they have no conflict of interest in the publication.
Figures
Similar articles
-
Characterization of gyrA and parC mutations in ciprofloxacin-resistant Pseudomonas aeruginosa isolates from Tehran hospitals in Iran.Iran J Microbiol. 2018 Aug;10(4):242-249. Iran J Microbiol. 2018. PMID: 30483376 Free PMC article.
-
The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.Braz J Microbiol. 2016 Oct-Dec;47(4):925-930. doi: 10.1016/j.bjm.2016.07.016. Epub 2016 Jul 26. Braz J Microbiol. 2016. PMID: 27522930 Free PMC article.
-
The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa.Iran J Pathol. 2021 Fall;16(4):426-432. doi: 10.30699/IJP.2021.520570.2542. Epub 2021 Jul 6. Iran J Pathol. 2021. PMID: 34567192 Free PMC article.
-
[Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):403-7. Zhonghua Yi Xue Za Zhi. 2003. PMID: 12820918 Chinese.
-
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543. J Antimicrob Chemother. 1997. PMID: 9372424
Cited by
-
Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.mSphere. 2021 May 19;6(3):e00202-21. doi: 10.1128/mSphere.00202-21. mSphere. 2021. PMID: 34011686 Free PMC article. Review.
-
Prevalence of colistin resistance in clinical isolates of Pseudomonas aeruginosa: a systematic review and meta-analysis.Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024. Front Microbiol. 2024. PMID: 39473844 Free PMC article.
-
Mutations in gyrB play an important role in ciprofloxacin-resistant Pseudomonas aeruginosa.Infect Drug Resist. 2019 Feb 8;12:261-272. doi: 10.2147/IDR.S182272. eCollection 2019. Infect Drug Resist. 2019. PMID: 30804676 Free PMC article.
-
The First Saudi Report of Novel and Common Mutations in the gyrA and parC Genes Among Pseudomonas Spp. Clinical Isolates Recovered from Taif Area.Infect Drug Resist. 2022 Jul 16;15:3801-3814. doi: 10.2147/IDR.S372027. eCollection 2022. Infect Drug Resist. 2022. PMID: 35875614 Free PMC article.
References
-
- Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone- resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother. 2001;45:2263–2268. doi: 10.1128/AAC.45.8.2263-2268.2001. - DOI - PMC - PubMed
-
- Alhazmi A. Pseudomonas aeruginosa–pathogenesis and pathogenic mechanisms. Int J Biol. 2015;7:44–67. doi: 10.5539/ijb.v7n2p44. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources